Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al.|Nature Medicine|2004Cited by 2k
Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical TrialJennifer S. Temel, David P. Ryan, Joseph A. Greer et al.|Journal of Clinical Oncology|2017Cited by 834
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R. Parikh, Ryan B. Corcoran, Ignaty Leshchiner et al.|Nature Medicine|2019Cited by 521
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasisMin Yu, Daniel A. Haber, David T. Ting et al.|Nature|2012Cited by 478
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419